Beiträge zur Onkologie. Contributions to Oncology Series Editors: Huber, H., Queisser, W. Vol. 49: Novel Approaches in Anticancer Drug Design Molecular Modelling — New Treatment Strategies Int. Symposium on Novel Appr. in Cancer Therapy, Heidelberg, December 1993 Editors: Zeller, W. J.; D'Incalci, M.; Newell, D. R. S. Karger, Basel, Freiburg 1995; VIII + 196 pp., 84 fig. 8 in color, 28 tab., hard cover Sfr 165.—/DM 198.—/US- $ 143.50, ISBN 3–8055–6043–5; $ 122.95

Autor: H. Schönenberger

Publikováno v: Archiv der Pharmazie. 328:739-739

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e014f609e9df35b1ca9b3d9e57107cbb
https://doi.org/10.1002/ardp.19953281010

Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

Autor: Johnson, N., Bentley, J., Wang, L-Z, Newell, D. R., Robson, C. N., Shapiro, G. I., Curtin, N. J.

Publikováno v: British Journal of Cancer; Sep2024, Vol. 131 Issue 5, p955-955, 1p

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.

Autor: Bowman, K J, Newell, D R, Calvert, A H, Curtin, N J

Publikováno v: British Journal of Cancer. 1/1/2001, Vol. 84 Issue 1, p106. 7p.

Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, ThymitaqTM) and paclitaxel

Autor: Hughes, A. N., Griffin, M. J., Newell, D. R., Calvert, A. H., Johnston, A., Kerr, B., Lee, C., Liang, B., Alan Boddy

Publikováno v: British Journal of Cancer
Scopus-Elsevier

A clinical study of nolatrexed dihydrochloride (AG337, ThymitaqTM) in combination with paclitaxel was performed. The aims were to optimize the schedule of administration and determine any pharmacokinetic (PK) interactions between the two drugs. In vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4298c24b22ce1c0db6207dd4868dce9e
http://europepmc.org/articles/PMC2363406

Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors

Autor: Gerrit Jansen, Schornagel, J. H., Westerhof, G. R., Rijksen, G., Newell, D. R., Jackman, A. L.

Publikováno v: Cancer Research, 50(23), 7544-8. American Association for Cancer Research Inc.
Scopus-Elsevier
Jansen, G, Schornagel, J H, Westerhof, G R, Rijksen, G, Newell, D R & Jackman, A L 1990, ' Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors ', Cancer Research, vol. 50, no. 23, pp. 7544-8 .

N10-Propargyl-5,8-dideazafolic acid (CB3717) and 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI-198,583) are potent folate-based inhibitors of thymidylate synthase. We studied the membrane transport and the growth-inhibitory effects of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f542d3e3e1c8e9c14844f441c2520e06
https://research.vumc.nl/en/publications/52dc2d47-869f-4c01-9387-f9eed0cad281